Research Analysts Set Expectations for TVTX FY2025 Earnings

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Investment analysts at Wedbush dropped their FY2025 EPS estimates for shares of Travere Therapeutics in a research note issued to investors on Tuesday, July 15th. Wedbush analyst L. Chico now expects that the company will earn ($0.74) per share for the year, down from their previous estimate of ($0.69). Wedbush has a “Outperform” rating and a $30.00 price target on the stock. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($1.40) per share. Wedbush also issued estimates for Travere Therapeutics’ Q4 2025 earnings at ($0.08) EPS and Q1 2026 earnings at ($0.05) EPS.

TVTX has been the subject of a number of other reports. Canaccord Genuity Group increased their target price on Travere Therapeutics from $45.00 to $47.00 and gave the company a “buy” rating in a research report on Thursday, April 10th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Travere Therapeutics in a research report on Wednesday, April 23rd. Citigroup lowered their target price on Travere Therapeutics from $35.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, June 11th. Stifel Nicolaus increased their target price on Travere Therapeutics from $22.00 to $23.00 and gave the company a “hold” rating in a research report on Friday, May 2nd. Finally, Scotiabank reiterated an “outperform” rating on shares of Travere Therapeutics in a research report on Friday, April 11th. Two equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Travere Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $32.14.

Travere Therapeutics Stock Down 0.9%

NASDAQ TVTX opened at $16.51 on Thursday. The company has a debt-to-equity ratio of 9.46, a quick ratio of 2.03 and a current ratio of 2.05. The company has a market capitalization of $1.47 billion, a P/E ratio of -5.88 and a beta of 0.72. Travere Therapeutics has a one year low of $7.93 and a one year high of $25.29. The stock has a 50 day moving average price of $15.95 and a 200-day moving average price of $18.06.

Travere Therapeutics (NASDAQ:TVTX) last released its earnings results on Thursday, May 1st. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.08. The company had revenue of $81.73 million during the quarter, compared to analyst estimates of $77.44 million. Travere Therapeutics had a negative net margin of 82.88% and a negative return on equity of 1,179.73%. The firm’s quarterly revenue was up 83.3% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.76) EPS.

Institutional Trading of Travere Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Summit Investment Advisors Inc. increased its stake in shares of Travere Therapeutics by 9.2% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,905 shares of the company’s stock valued at $138,000 after buying an additional 667 shares during the period. Arizona State Retirement System increased its stake in shares of Travere Therapeutics by 4.3% during the first quarter. Arizona State Retirement System now owns 23,364 shares of the company’s stock valued at $419,000 after buying an additional 968 shares during the period. E Fund Management Co. Ltd. increased its stake in shares of Travere Therapeutics by 8.6% during the first quarter. E Fund Management Co. Ltd. now owns 13,553 shares of the company’s stock valued at $243,000 after buying an additional 1,072 shares during the period. Diversified Trust Co increased its stake in shares of Travere Therapeutics by 8.6% during the first quarter. Diversified Trust Co now owns 15,959 shares of the company’s stock valued at $286,000 after buying an additional 1,258 shares during the period. Finally, Oak Ridge Investments LLC increased its stake in shares of Travere Therapeutics by 2.8% during the first quarter. Oak Ridge Investments LLC now owns 54,070 shares of the company’s stock valued at $969,000 after buying an additional 1,471 shares during the period.

Insiders Place Their Bets

In other Travere Therapeutics news, CEO Eric M. Dube sold 18,924 shares of the stock in a transaction on Monday, May 5th. The stock was sold at an average price of $21.05, for a total value of $398,350.20. Following the sale, the chief executive officer owned 419,173 shares in the company, valued at $8,823,591.65. This trade represents a 4.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Christopher R. Cline sold 1,784 shares of the stock in a transaction on Monday, May 5th. The stock was sold at an average price of $21.05, for a total value of $37,553.20. Following the completion of the sale, the chief financial officer owned 93,126 shares in the company, valued at approximately $1,960,302.30. The trade was a 1.88% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 23,294 shares of company stock worth $485,123 over the last quarter. Company insiders own 4.19% of the company’s stock.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.